British Society for Immunology

The Inner Circle Acknowledges, Ian A. Wilson as a Distinguished Healthcare Professional for his contributions to the Biomedical Research and Infectious Disease Fields

Retrieved on: 
Tuesday, September 5, 2023
Faculty, University of Oxford, National academy, Scripps Research, Society, University, TSRI, Structure, Therapy, Education, Vaccination, Academia Sinica, Journal of Experimental Medicine, SARS-CoV-2, Infection, Biomedical Research, American Academy, Royal, Research, Multimedia, Antibody, Inner circle, Biology, American Crystallographic Association, Molecular biology, British Society for Immunology, Publication, Newcomb Cleveland Prize, Medical research, Laboratory, Journal, Structural biology, University of Edinburgh, Harvard Society of Fellows, AAAS, HIV, Royal Society, Journal of Molecular Biology, Corpus Christi College, Computational biology, Nursing, Vaccine, Science, Biochemistry, Immunology

JOLLA, Calif., Sept. 5, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Ian A. Wilson is acknowledged as a Distinguished Healthcare Professional for his contributions to the Biomedical Research and Infectious Disease Fields.

Key Points: 
  • JOLLA, Calif., Sept. 5, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Ian A. Wilson is acknowledged as a Distinguished Healthcare Professional for his contributions to the Biomedical Research and Infectious Disease Fields.
  • Dr. Wilson pursued higher education at the prestigious University of Edinburgh in Scotland in 1971 where he earned a Bachelor of Science degree in Biochemistry.
  • In this post, he directed a laboratory involved in biomedical research on infectious diseases.
  • He currently serves as a Professor at Scripps Research (formerly The Scripps Research Institute or TSRI) in La Jolla, California.

MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022

Retrieved on: 
Tuesday, December 6, 2022
Research, Clinical Trials, Biotechnology, Other Health, Managed Care, Health, Pharmaceutical, Other Science, Science, Society, RA, Mouse, TNF, Genta (company), Rheumatoid arthritis, MD, Infection, CAIA, Chronic pain, Patient, Annual report, British Society for Immunology, Ankylosing Spondylitis Quality of Life, FDA, Degenerative disease, COVID-19, CB2, Inflammation, Trial of the century, Ageing, Safety, Arthritis, Congress, Autoimmunity, BSI, Warfarin necrosis, Anxiety, Seizure, CNS, Pharmaceutical industry, Dietary supplement, CBD, Research, Clinical Trials, Biotechnology, Other Health, Managed Care, Health, Pharmaceutical, Other Science, Science

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, is presenting data today at the 2022 British Society for Immunology (BSI) Congress in Liverpool, England.

Key Points: 
  • MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, is presenting data today at the 2022 British Society for Immunology (BSI) Congress in Liverpool, England.
  • In-life results showed percent change of inflammation relative to control was reduced by 37% with MYMD-1 while reduction was 29% with etanercept at 10 mg/kg/day.
  • Its ease of oral dosing is a significant differentiator compared to currently available TNF- inhibitors, all of which require delivery by injection or infusion.
  • MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), is a clinical stage biopharma company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases.

MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress

Retrieved on: 
Thursday, November 17, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, FDA, Warfarin necrosis, Anxiety, Chronic pain, British Society for Immunology, CB2, CAIA, Rheumatoid arthritis, Thyroiditis, Sarcopenia, Patient, Ageing, Pharmacology, RA, Human, Inflammation, CNS, BSI, Safety, MS, Immune system, Degenerative disease, Society, Arthritis, Frailty, Annual report, Congress, Central nervous system, Multiple sclerosis, COVID-19, Seizure, TNF, Genta (company), Pharmaceutical industry, CBD

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, has been invited to present late-breaking data at the 2022 British Society for Immunology (BSI) Congress in Liverpool, England.

Key Points: 
  • MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, has been invited to present late-breaking data at the 2022 British Society for Immunology (BSI) Congress in Liverpool, England.
  • We believe strongly in the potential of MYMD-1 as a next-generation TNF- inhibitor.
  • MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), is a clinical stage biopharma company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases.
  • Forward-looking statements speak only as of the date they are made and none of MyMD nor its affiliates assume any duty to update forward-looking statements.

Biosimilar Interleukins Global (IL-17, IL-23, IL-1, IL-5, IL-6, Others) Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 21, 2021
Biotechnology, Hospitals, Health, Pharmaceutical, Clinical Trials, Autoimmune disease, IL-5, Growth, Interleukin, Degenerative disease, Cell, British Society for Immunology, Society, Psoriasis, IL-6, Rheumatoid arthritis, Immunology, COVID-19, Asthma, IBD, Inflammatory bowel disease, Incidence, Sorrento, Cancer, Prevalence, Pharmacy, Generic drug, Vaccine

The "Biosimilar Interleukins Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biosimilar Interleukins Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the biosimilar interleukins market are MabPharm, Gedeon Richter, Bio-Thera Solutions, Sorrento Therapeutics/MabTech, and Sunshine Guojian Pharmaceutical.
  • The biosimilar interleukins market consists of sales of interleukin biosimilars generated by the establishments that manufacture interleukin biosimilars that are used to treat various autoimmune diseases.
  • The biosimilar interleukins market covered in this report is segmented by type into IL-17, IL-23, IL-1, IL-5, IL-6, and others.